GlassScriptPhysician profile
Melissa M Cyr
NPI 1780686212
$2,450.23
in general payments reported to CMS, 2019-2025
27 companies · $1,089 in 2025
The $1,089 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.89 · 2023: $173 · 2024: $1,151 · 2025: $1,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,314 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,314.34 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $571.50 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $338.01 | 2021-2025 | Opdivo, Augtyro |
| Astrazeneca Pharmaceuticals LP | $233.50 | 2024-2025 | Lynparza, Imfinzi, Enhertu |
| Abbvie INC. | $166.23 | 2025 | |
| Pfizer INC. | $164.65 | 2024-2025 | |
| Array Biopharma INC | $130.05 | 2023-2025 | Mektovi, Braftovi, Lorbrena |
| Lilly USA, LLC | $120.21 | 2024-2025 | Retevmo, Jaypirca, Verzenio |
| Daiichi Sankyo INC. | $94.83 | 2024-2025 | Vanflyta, Injectafer, Datroway |
| Celgene Corporation | $93.63 | 2024 | Opdivo, Reblozyl |
| Merck Sharp & Dohme LLC | $70.75 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Acrotech Biopharma INC. | $61.95 | 2021-2025 | Beleodaq |
| Janssen Biotech, INC. | $44.59 | 2024-2025 | Carvykti |
| Takeda Pharmaceuticals U.S.A., INC. | $41.72 | 2024 | Alunbrig |
| Rigel Pharmaceuticals, INC. | $38.35 | 2024 | Rezlidhia, Tavalisse |
| Amgen INC. | $32.40 | 2023 | Kyprolis |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $31.80 | 2025 | Danziten |
| Beone Medicines USA, INC. | $25.43 | 2025 | Tevimbra |
| Adc Therapeutics America, INC. | $24.35 | 2024 | |
| Springworks Therapeutics, INC. | $23.58 | 2025 | Ogsiveo |
| Pharmaessentia USA Corporation | $21.98 | 2025 | Besremi |
| Alexion Pharmaceuticals, INC. | $21.60 | 2025 | Ultomiris |
| Genmab U.S., INC. | $19.62 | 2024 | Tivdak |
| Taiho Oncology, INC. | $19.39 | 2025 | |
| Blueprint Medicines Corporation | $18.09 | 2025 | Ayvakit |
| Eisai INC. | $16.10 | 2024 | |
| Glaxosmithkline, LLC. | $14.00 | 2024 | Ojjaara |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Cyr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.